Virginia Ruth Sanzone Sells 930 Shares of ICU Medical (NASDAQ:ICUI) Stock

ICU Medical, Inc. (NASDAQ:ICUI) VP Virginia Ruth Sanzone sold 930 shares of ICU Medical stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total value of $132,376.20. Following the transaction, the vice president owned 5,456 shares in the company, valued at $776,607.04. This represents a 14.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

ICU Medical Stock Down 0.4%

Shares of ICU Medical stock opened at $138.53 on Friday. ICU Medical, Inc. has a 1 year low of $107.00 and a 1 year high of $175.51. The company has a market cap of $3.42 billion, a P/E ratio of -91.14 and a beta of 0.83. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63. The stock has a 50-day moving average price of $125.24 and a 200 day moving average price of $128.39.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.43 by $0.60. The company had revenue of $533.30 million for the quarter, compared to the consensus estimate of $511.46 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The firm’s quarterly revenue was down 8.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.59 EPS. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. As a group, analysts expect that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Institutional Investors Weigh In On ICU Medical

Several institutional investors and hedge funds have recently modified their holdings of ICUI. Kennedy Capital Management LLC increased its position in ICU Medical by 991.8% during the third quarter. Kennedy Capital Management LLC now owns 127,297 shares of the medical instruments supplier’s stock worth $15,271,000 after buying an additional 115,638 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of ICU Medical during the 3rd quarter worth about $416,000. Sei Investments Co. increased its holdings in shares of ICU Medical by 9.4% during the 3rd quarter. Sei Investments Co. now owns 34,346 shares of the medical instruments supplier’s stock valued at $4,120,000 after acquiring an additional 2,943 shares during the last quarter. UBS Group AG increased its holdings in shares of ICU Medical by 239.8% during the 3rd quarter. UBS Group AG now owns 386,555 shares of the medical instruments supplier’s stock valued at $46,371,000 after acquiring an additional 272,782 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its stake in shares of ICU Medical by 99.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,905 shares of the medical instruments supplier’s stock valued at $588,000 after acquiring an additional 2,446 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

Analyst Upgrades and Downgrades

ICUI has been the topic of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a research note on Wednesday, October 8th. KeyCorp boosted their price target on shares of ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Piper Sandler increased their price objective on ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a research report on Friday, September 5th. Finally, Raymond James Financial lowered their target price on ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $181.75.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.